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The development of immunotherapeutic methods for the treatment of oncological
diseases have made it possible to improve the effectiveness of standard therapies.
There was no breakthrough after first using of personalized therapeutic vaccines based
on dendritic cells in clinical practice. A deeper study of the biology of dendritic cells, as well
as the use of new approaches and agents for antigenic work, have made it possible to
expand the field of application of dendritic cell (DC) vaccines and improve the indicators of
cancer patients. In addition, the low toxicity of DC vaccines in clinical trials makes it
possible to use promising predictions of their applicability in wider clinical practice. This
review examines new approaches and recent advances of the DC vaccine in clinical trials.
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Immunotherapeutic methods have opened up new possibilities for the treatment of cancer. Therapeutic
anticancer vaccines, in particular DC vaccines, have played a significant role in the development of these
methods (1). The mechanism of action of DC vaccines is to stimulate and support an immune response
aimed exclusively at the elimination of tumor cells in the body. Dendritic cells (DCs), along with
macrophages and B-cells, have major histocompatibility complex (MHC) -II molecules on their
membrane surface which make them professional antigen-presenting cells (APCs). But only DCs, due
to their ability to migrate to the lymph nodes, have the ability to activate T-killers – the main cells in the
antitumor immune response (2, 3). The general approach for creating DC vaccines is to isolate dendritic
cells or their precursors from human blood, further maturation and activation of cells using a cytokine
cocktail and autologous tumor antigens ex vivo, followed by administrating of autologous mature activated
DCs back into the body (Figure 1). Once in the lymph nodes, DCs carry out antigen presentation for
CD4+ and CD8+ T-cells, activating the cell-mediated and humoral adaptive immune system. Moreover,
these vaccines can act as a safe adjunct to complex anticancer therapy, thus enhancing the therapeutic
effects of chemotherapy (4) or other immunotherapeutic methods such as immune checkpoint inhibitors
(ICIs) (5). Sipuleucel-T – the first FDA-approved immunotherapeutic drug based on autologous DCs
treated with the recombinant prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) fusion, has shown not only no toxic effects, but also positive prospects in
therapeutic approaches for the treatment of prostate cancer (6). Sipuleucel-T is currently being tested in
clinical trials in combination with other anticancer therapies (NCT01804465, NCT02463799,
NCT01881867). Nowadays, after numerous clinical trials, DC vaccines have shown low efficacy in the
treatment of solid and hematological tumors. However, DC vaccines in combination with other anticancer
therapy can be hopefully become a tool, aimed at organizing a targeted antitumor T-cell response.September 2021 | Volume 11 | Article 7308241
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DENDRITIC CELLS
Nowadays, there is no single optimal method to generate DCs.
Under culture (ex vivo) DCs can be obtained in two ways:
differentiation of DCs from peripheral blood monocytes or
from CD34+ hematopoietic stem cells (HSC). Cytokines suchFrontiers in Oncology | www.frontiersin.org 2as GM-CSF and IL-4 are required for differentiation of immature
DCs from monocytes derived from human peripheral blood.
Using this method, the process of obtaining immature moDCs
takes 5-7 days. After that, immature DCs are stimulated with a
cytokine cocktail (IL-1b, IL-6, TNF-a or CD40L and prostaglandin
(PGE)-2 or TLR agonists) for 48 hours to produce a mature
moDC (7).A
B
FIGURE 1 | (A) The main stages of creating a personalized antitumor vaccine based on autologous DCs. The figure shows various methods for obtaining DCs from
CD14+ monocytes, CD34+ HSCs and natural DCs from patient’s whole blood by apheresis, further maturation using a cocktail of cytokines or electroporation of
mRNA of CD40L, CD70 and caTLR4. Methods for obtaining various types of tumor antigens are also shown, such as: artificial neoantigens/peptides/mRNA of tumor
antigens, lysate/inactivated tumor cells, as well as extracellular vesicles for activating DCs and their subsequent use as a DC vaccine. (B) After the administration of
the dendritic vaccine, activated mature DCs migrate to the lymph nodes, where they present tumor antigens to naïve CD8+ and CD4+ T-cells and B-cells. Activated
CD8+ and CD4+ T-cells and B-cells migrate to the adjacent tumor tissue, where tumor cells are eliminated by activated cytotoxic CD8+ T-cells and NK cells, while
CD4+ T-helpers and B-cells releasing pro-inflammatory cytokines, that enhance cytotoxic effects.September 2021 | Volume 11 | Article 730824
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used mRNAs encoding proteins CD40L, CD70, and constitutively
active TLR4 (caTLR4) (TriMix-DC), which were electroporated into
DCs. TriMix-DCs that were given to all patients were characterized
by amature phenotype and secretion of IL-12p70 (8). There is also a
method for culturing polarized a-type 1 DCs (aDC1), which are
capable of producing high levels of IL-12 and inducing long-lived
type 1 T-cell responses against tumor associated antigens more
efficiently than standard mature DCs. The following cytokine
cocktail for DCs maturation was used: IL-1b, TNF-a, IFN-a,
IFN-g and polyinosinic:polycytidylic acid (poly-I:C) (9).
Another method of obtaining DCs from CD34+ HSCs,
derived from bone marrow by administering GM-CSF to
patients prior to leukapharesis which involves culturing the
harvested cells for 1 week in the presence of GM-CSF, TNF-a,
and recombinant fms-like tyrosine kinase 3 ligand (Flt3L). As a
result, DCs are obtained, which are phenotypically similar to
Langerhans and myeloid cells at different stages of differentiation.
Such CD34-HSCs-derived DCs also have an important influence
on the T-cell response as they can induce a cellular or humoral
immune responses depending on their differentiation into either
LCs or dermal CD14+ DCs (10, 11).
There is also a method for generating circulating DCs in vivo
by administering growth factors for hematopoietic cells like Flt3L
or G-CSF (12). Some studies use natural myeloid DCs to create a
DC vaccine. The main advantage of using natural DCs instead of
moDCs is that the short-term ex vivo exposure needed to activate
cells and load them with tumor antigens, usually it takes less than
24 hours. This advantage can preserve their functionality better
and prevent depletion. However, their numbers can be significantly
lower than moDCs or CD34-HSCs-derived DCs (13).METHODS FOR ACTIVATING
DENDRITIC CELLS
Various methods are currently being used to activate DCs in vivo in
order to overcome suppression of the immune system by tumors.
TLRs are the main class of cellular receptors responsible for
recognizing foreign microorganisms or viruses. Synthetic agonists
of the TLR receptors can influence the depth of antitumor T-cell
responses. TLR7 agonists such as imiquimod, for example,
stimulated immune-mediated rejection of primary skin metastases
when it was applied topically in breast cancer patients (14).
Poly-I:C is another antitumor therapy of interest as it is an
immunostimulating agent that interacts with TLR3 and thereby
induces the maturation of DCs, as well as the production of IL-12,
type I IFNs and chemokines. A less toxic variant, poly-ICLC, is a
poly-I:C mixed with the stabilizers carboxymethylcellulose and
polylysine. It is used either alone or as an adjuvant to the main
anticancer therapy (15). In one recent multicenter randomized
phase II trial, patients were divided into two groups and
vaccinated with CDX-1401 (human anti-DEC-205 mAb) + poly-
ICLC, with or without CDX-301 (Flt3L) pretreatment
(NCT02129075). Patients in the group receiving Flt3L showed
increased numbers of activated DCs, natural killers (NK) and T-
cells, but also exhibited an increase in T-cell responses, whichFrontiers in Oncology | www.frontiersin.org 3increased the effectiveness of the vaccine. Furthermore, poly-ICLC
enhanced the antigen-presenting activity of DCs (16).
There have also been attempts to enhance antitumor effects by
combining DC vaccines with a lentiviral vector encoding anti-
TGF-b1 shRNA (shTGF-b1) (17). Lentivirus (LV) was injected
into mouse tumors the day before DC vaccine administration.
However, the combination of LV shTGF-b1 with the DC vaccine
was insufficient for long-term tumor suppression of TGF-b1 (18).
In order to obtain a complete DC vaccine, autologous mature
DCs obtained from mononuclear cells or CD34+ HSC are
activated ex vivo. The process of antigenic loading of DCs ex
vivo is performed in various ways including via: inactivated tumor
cells (19), tumor lysate (20), tumor vesicles (21, 22), synthesized
tumor peptides (13) or synthesized mRNA of tumor antigens (8).CLINICAL TRIALS
Carcinoma
The search for approaches towards developing and testing DC-
based vaccines continues, despite the difficulties associated with
low efficacy (Table 1). It was shown that a vaccine composed of
monocyte-derived autologous Th17-inducing DCs pulsed with
folate receptor alpha (FRa) epitopes was highly immunogenic
and promoted the prolongation of the remission period in
patients with ovarian cancer. At the same time, no adverse effects
(AEs) at grade 3 or higher were found (28). In a study by Nagai et
al., an adherent population of peripheral blood mononuclear cells
was used to create a vaccine based on DCs. These cells were
stimulated by a number of factors to produce mature DCs, and
then pulsed with Wilms tumor gene 1 (WT1) peptide and Mucin 1
(MUC1), this vaccine was shown to be effective in a Phase I/IIa
Clinical Trial in patients with adenocarcinoma without AEs of
grade 2 or higher (29). The safety of DC-based vaccines has been
demonstrated in patients with hepatocellular carcinoma using
HSP70 mRNA-transfected DCs. 75% of the patients had AEs of
grade 1 or 2, however, the incidence of all AEs between the control
and DC groups were comparable, since most AEs were associated
with liver disease. In the DC group, 10% of patients had AEs of
grade 3, which included anemia and thrombocytopenia (30).Melanoma
It has been shown that a vaccine based on moDCs loaded with
tumor lysate affects the tumor microenvironment (TME) and
promotes the transformation of a “cold” tumor into a “hot” one
through activation and infiltration of CD8+T-lymphocytes, but it
also affects up-regulation of PD-L1 expression in patients with
metastatic melanoma (31). A total of 21 patients participated in the
trial and the median overall survival (OS) was 22 months. One
patient achieved a complete response (CR), two had partial
responses (PR), and nine patients were classified as having a
stable disease (SD). The aspect of the change in the expression of
PD-L1 of tumor cells after the application of the DC vaccine, on the
one hand, indicates the activation of the tumor “escape” processes,
but, on the other hand, makes it possible to include an effective
additional immunotherapy using ICIs in the treatment processSeptember 2021 | Volume 11 | Article 730824
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to be effective. 51 melanoma patients treated with ICIs following
recurrence had an adjuvant DC vaccination. The response rate with
pembrolizumab or nivolumab alone was 52%, and 35% responded
to ipilimumab monotherapy. The effectiveness of ipilimumab in
combination with nivolumab was 75% (5).
A vaccine based on moDCs electroporated with mRNA
encoding CD40 ligand, CD70 and a caTLR4 (TriMixDC) has
also been tested in melanoma patients. Effective antigenic
loading was achieved by coelectroporation of TriMixDC with
full-length mRNA encoding HLA-II proteins and melanoma-
associated genes (MAA): MAGE-A3, MAGE-C2, tyrosinase or
gp100, (TriMixDC-MEL), which allows presentation of the full
spectrum of antigenic peptides and leads to a broader MAA-
specific T-cell response. CR was observed in two out of 15
patients, and PR was also observed in two patients. Median
progression-free survival (PFS) and OS were 5 months (95%
confidence interval (CI), 0 to 10) and 14 months (95% CI, 5 to
23), respectively. No serious grade 3 or 4 toxicity was observed,
however all patients had grade 2 local skin reactions (irritation,
erythema and edema) at the injection sites. In addition, post-
infusion grade 2 chills were observed in 3 of 15 patients (8).
In phase II clinical trials, in contrast to the previous study, in
addition to TriMixDC-MEL, therapy with checkpoint inhibitors,
in particular, ipilimumab, was used. Among 39 patients treated,
20% were reported with CR and 18% with PR. The estimated
median PFS was 27 weeks (95% CI, 9 to 44) and the estimated
median OS was 59 weeks (95% CI, 40 to 79). 64% of patients
died as a result of a progressive disease. All patients had skin
reactions at the injection site of TriMixDC-MEL grade 2, and
some patients had chills (grade 1-2) and flu-like symptoms. 36% of
patients developed treatment-related grade 3 or 4 AEs. In 64% of
patients, grade 1-2 dermatitis was registered. All treatment-related
AEs were reversible with the exception of hypopituitarism (23).
TriMixDC-MEL was used also used as an adjuvant in phase II
randomized controlled clinical trials for patients with stage III/
IV melanoma who did not have the disease after removal of
macrometastases. This vaccine has been shown to be well
tolerated by patients and to improve patient survival over theFrontiers in Oncology | www.frontiersin.org 4course of a year. However, despite the promising results, patients
in the TriMixDC-MEL group had a higher rate of early local-
regional relapse compared to the control group. No AEs of grade
3 or higher were identified, but 80% of patients reported swelling
and erythema at the site of intradermal DC-injection (33). What
is more, in a recent prospective, randomized, phase II clinical
trial, a DC vaccine in combination with cisplatin in stage III
and IV melanoma patients was feasible and safe, but this
combination did not improve clinical outcomes when
compared to DC vaccination monotherapy (24).
Autologous natural myeloid DCs have also been used to treat
melanoma patients. One such study included 15 patients with
stage IV or inoperable stage IIIc metastatic melanoma. DCs were
loaded directly with HLA-A*0201-restricted melanoma-
associated peptides (gp100 and tyrosinase). The mean PFS was
17.6 months for patients with functional T-cells in their blood
and skin-infiltrating T-lymphocytes (SKIL) producing IFN-g.
The mean OS of patients with functional T-lymphocytes was
29.0 months. There were no vaccine-related side effects, with the
exception of one patient with grade 1 pain at the injection site
and 4 patients with grade 1 fatigue (13).
A DC vaccine with natural myeloid DCs loaded with peptides
is currently in a clinical trial for the treatment of stage 3
melanoma patients (NCT02993315). In addition, patients are
still being recruited for phase I clinical trials of a personalized
vaccine created by autologous DCs treated with autologous
whole tumor cell lysate in combination with the chemotherapy
drug cyclophosphamide to treat advanced solid tumor patients
with high tumor mutation burden (NCT03671720).
Glioma
Glioblastoma multiforme (GBM) is one of the most common
primary malignant brain tumors and is characterized by low
patient life expectancy, “inaccessibility” for activated T-cells, and
high genetic variability (34). It was shown that after the use of a
DCVax®-L vaccine (DCs loaded with autologous tumor lysate),
33% of patients reached or exceeded the median life expectancy
(48 months), and 17% of patients reached or exceeded the
median life expectancy of 72 months in phase I/II clinicalTABLE 1 | Effectiveness of personalized therapeutic DC vaccine in combination with other antitumor therapy methods.
Combination therapy Cancer type Efficiency, (%) Ref.
PD-1 inhibition monotherapy after DC vaccination Metastatic melanoma CR=24, PR=28, ST=21, PD=28, mPFS=13.1
(months), mOS=32.5 (months)
(5)
Ipilimumab monotherapy after DC vaccination CR=20, PR=15, ST=15, PD=50, mPFS=3.9
(months), mOS=30.0 (months)
Ipilimumab- nivolumab after DC vaccination CR=25, PR=50, PD=25, mPFS=5.6 (months),
mOS= NR
TriMixDC-MEL with ipilimumab Melanoma CR=20, PR=18, mPFS=27 (weeks), mOS=59
(weeks)
(23)
DC vaccination with cisplatin IV stage melanoma mPFS=4.7 (months), mOS=12.2 (months) (24)
DCVax-L with radiotherapy and temozolomide Glioblastoma mOS=23.1 (months) (25)
DC vaccination in combination with low-dose cyclophosphamide, poly I:C,
imiquimod and anti-PD-1 antibody.
Glioblastoma multiforme mOS=19 (months) (26)
NSCLC mOS=17 (months)
IFN-DC with low-dose intra-tumoral rituximab Relapsed/Refractory
Follicular Lymphoma
CR=37, PR=12.5, mPFS=13.5 (months) (27)September 2021 | Volume 11 | Article 73*CR, complete response; PR, partial response; ST, stable disease; PD, progressive disease; mPFS, median progression-free survival; mOS, median overall survival; NR, no results;
NSCLC, non-small cell lung cancer.0824
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1 and 2 included headache, nausea, loss of appetite, diarrhea, fatigue
and low-grade fever (35). DCVax®-L is currently being tested in a
phase III clinical trial in patients after glioblastoma resection in
combination with radiation and chemotherapy. Median OS was
23.1 months from surgery, and vaccination-related grade 3 or 4 AEs
were observed in only 2.1% of patients (25).
A study conducted on patients with high-grade glioma showed
encouraging results in a phase II clinical trial using a-type-1 DCs
pulsed with a cocktail of 5 synthetic peptides derived from
enriched monocytes in the presence of a cytokine cocktail (36).
In a study by Wang et al. DCs loaded with tumor-associated
antigens (TAA) and/or mRNA of neoantigens have been used in
a small group of glioma patients in combination with low-dose
cyclophosphamide to regulate T-cell depletion, poly-I:C, and
imiquimod. As a result of this study, it was shown that loading
DCs with TAA and the mRNA of neoantigens increased the life
expectancy of patients. The median OS was 19 months and no
grade 3 or higher AEs were observed (26).
Sarcoma
A therapeutic vaccine based on moDCs loaded with antigens
from a patient’s tumor has been shown to be safe in phase I/II
academic clinical trials in pediatric patients with high-risk
metastatic tumors, mainly sarcomas and neuroblastomas. Besides
these outcomes, the study showed that certain combinations of
anticancer drugs (temozolomide + irinotecan), as well as a
combination (pazopanib + topotecan + cyclophosphamide), prior
to cell isolation in patients, negatively affected the maturation of
DCs and reduced their immunostimulating properties (37).
Сombinations of DCs loaded with tumor lysate with imiquimod
(Aldara®) and gemcitabine (Gemzar®) in sarcoma patients are now
in active phase (NCT01803152). Favorable results of DC testing
were obtained in young patients and children with soft tissue
sarcoma. Intratumoral administration of DCs, in combination
with radiation doses and subsequent tumor resection, resulted in
the absence of systemic relapses in 11 out of 18 patients within 2-8
years. There were no grade 4 or 5 toxicities and no treatment-
related deaths were observed. The median OS was 57 months (38).
Patients with recurrent or refractory Ewing’s sarcoma who received
intradermal vaccine administration based on moDC loaded with
tumor lysate did not have a pronounced clinical response, however,
some of them showed activation of the T-cell immune response.
Probably disappointing clinical response data are associated with
prior treatment, which had a serious immunosuppressive effect, as
well as advanced disease and extensive lesions (39).
Lymphoma
Hematologic malignancies are of particular interest for DC-based
therapies, as they usually present with multiple areas of immune
dysregulation. In a study by Cox et al. moDCs generated in the
presence of IFN-a and GM-CSF (IFN-DC), in combination with
low doses of rituximab, were administered intranodally in a phase I
clinical study in patients with follicular lymphoma. Interestingly,
even in the absence of “loading” these cells with TAA, impressive
immunological responses were recorded in some patients and
regression of some areas not undergoing therapy. No grade 3 orFrontiers in Oncology | www.frontiersin.org 5higher AEs were observed (27). In another study immunological
responses to anti-PD-1 antibodies (pembrolizumab) were evaluated
in combination with the intranodal administration of the Lymvac-1
vaccine in patients with follicular lymphoma (NCT02677155). A
clinical trial in non-Hodgkin’s lymphoma patients with DCs in
combination with pembrolizumab and cryosurgery is presently in
the active phase (NCT03035331). An earlier similar clinical trial,
but using just intratumoral DCs and cryoablation, has already been
shown to be safe for patients (NCT01239875) (40).CONCLUSION
The first attempts at DC-based vaccines were made over 20 years
ago, but the results have not been encouraging. Researchers faced
particular difficulties while DC vaccine was being developed.
Differentiation antigens or overexpressed tumor antigens were
used as the target antigen. However negative selection in the
thymus limits the formation of cytotoxic T-lymphocytes with
high avidity directed against these antigens. In order to avoid this
problem, scientists identified neoantigens recognized by tumor
infiltrating lymphocytes (TILs), and certain adjuvants increased
the immunostimulatory effect and activation of DCs. Though,
tolerogenicity and dysfunction of DCs in the TME became the
main problems with DC vaccines. It is important to improve our
knowledge regarding regulating these processes. The accumulation
of knowledge about the biology of DCs, as well as the development
of new approaches towards treating malignant neoplasms, have
allowed scientists to improve existing technologies and increase the
effectiveness of developments based on DCs. Thus, despite their
limited effectiveness, DC vaccine technology is promising in
relation to aspects linked to personalized medicine, clinical safety
and is most effective in combination with other therapeutic
approaches. In addition, it should be borne in mind that the
majority of patients receiving experimental DC-based drugs were
in the terminal stages of the disease. In summary, DC vaccines in
combination with another immunotherapeutic or traditional
anticancer methods inspire hope for the treatment of patients at
earlier disease development stages or to delay or prevent relapse
and metastasis, as DC vaccines have exhibited an increase in the
survival rate of responded patients with advanced stages of
oncological disease, and also had a significant effect on the
destruction of distant metastatic foci.AUTHOR CONTRIBUTIONS
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